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SoxF factors induce Notch1 expression via direct transcriptional
regulation during early arterial development
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ABSTRACT
Arterial specification and differentiation are influenced by a number of
regulatory pathways. While it is known that the Vegfa-Notch cascade
plays a central role, the transcriptional hierarchy controlling arterial
specification has not been fully delineated. To elucidate the
direct transcriptional regulators of Notch receptor expression in
arterial endothelial cells, we used histone signatures, DNaseI
hypersensitivity and ChIP-seq data to identify enhancers for the
humanNOTCH1 and zebrafishnotch1b genes. These enhancerswere
able to direct arterial endothelial cell-rAQ3
¶
estricted expression in transgenic
models. Genetic disruption of SAQ4
¶
oxF binding sites established a clear
requirement for members of this group of transcription factors (SOX7,
SOX17 and SOX18) to drive the activity of these enhancers in vivo.
Endogenous deletion of the notch1b enhancer led to a significant
augmentation of arteriovenous defects in Notch pathway-deficient
zebrafish. Loss of SoxF function revealed that these factors are
necessary for NOTCH1 and notch1b enhancer activity and for correct
endogenous transcription of these genes. These findings position
SoxF transcription factors directly upstream of Notch receptor
expression during the acquisition of arterial identity in vertebrates.
KEY WORDS: Notch1, SoxF, Artery, Arterial enhancer, Endothelial
cell, Transcriptional regulation, Zebrafish, Human, Mouse
INTRODUCTION
Genetic specification of arterial fate has long been attributed to
regulation downstream of the Vegfa and Notch pathways. Vegfa
signalling is essential for arterial specification in both zebrafish and
mammalian models, at least partially by stimulating the expression
of components of the Notch pathway, while activation of Notch
signalling can rescue defects in Vegfa-deficient zebrafish embryos
(Lanahan et al., 2010; Lawson et al., 2002; Liu et al., 2003; Visconti
et al., 2002). The Notch receptors Notch1 and Notch4 and the delta-
like ligands Dll1, Dll4, Jag1 and Jag2 are expressed in endothelial
cells, where they play crucial roles in both arteriogenesis and
angiogenesis (Lawson et al., 2002; Liu et al., 2003; Phng and
Gerhardt, 2009; Roca and Adams, 2007). Ligand binding to the
Notch receptor releases the Notch intracellular domain (NICD),
which translocates to the nucleus and forms a transcriptional
activation complex with the otherwise repressive DNA-bound Rbpj
[CSL, Su(H)] (Bray, 2006). Combined ablation of Notch1 and
Notch4, which are both principally expressed in arterial endothelial
cells during early vascular remodelling (Chong et al., 2011; Jahnsen
et al., 2015), results in severe vascular remodelling defects (Krebs
et al., 2000), as does ablation of the Notch downstream effector
Rbpj or of Dll4, a Notch ligand specific to a AQ5
¶
rteries within the
vasculature (Duarte et al., 2004; Gale et al., 2004; Krebs et al.,
2004). However, loss of Notch signalling does not fully recapitulate
the arterial defects downstream of Vegfa ablation (Carmeliet et al.,
1996; Krebs et al., 2000; Lawson et al., 2002), and the arterially
restricted gene expression patterns of components of the Notch
pathway do not fully overlap with activated Vegfa (Lawson, 2003),
suggesting that additional factors are involved in the regulation of
Notch-mediated arterial fate.
The SoxF group of transcription factors (Sox7, Sox17 and
Sox18) are expressed in endothelial cells from early in development
(Francois et al., 2010). While each SoxF member displays a
subtly different endothelial expression pattern, all three factors are
expressed early in arterial development (Corada et al., 2013;
François et al., 2008; Zhou et al., 2015) and share considerable
functional redundancy, complicating interpretation of the
consequences of gene disruption (Hosking et al., 2009; Zhou
et al., 2015). Combined loss of sox7 and sox18 in zebrafish, both by
morpholino-based knockdown and genetic mutation, resulted in
serious arteriovenous malformations similar to those seen after
Notch ablation, suggesting that SoxF factors might genetically
interact with the Notch pathway in endothelial cells (Cermenati
et al., 2008; Hermkens et al., 2015; Herpers et al., 2008; Lawson
et al., 2001). Further evidence was provided in mice, where
endothelial-specific ablation of Sox17 caused arterial differentiation
and remodelling defects (Corada et al., 2013), and conditional
deletion of SoxF factors in the adult resulted in loss of major vessel
identity in the retina (Zhou et al., 2015). Inhibition of Vegfa
signalling can significantly impact SoxF expression and activity in
both mouse and zebrafish models (Kim et al., 2016; Pendeville
et al., 2008; Duong et al., 2014; Pennisi et al., 2000b), suggesting
that members of the SoxF family lie downstream of Vegfa.
Further, SoxF acts in a positive feed-forward loop to maintain Flk1
(Kdr; kdrl in zebrafish) expression (Kim et al., 2016). By contrast,Received 28 October 2016; Accepted 7 June 2017
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the ablation of Notch signalling in the vasculature does not
significantly impact the expression of SoxF (Abdelilah et al., 1996;
Corada et al., 2013). Different experimental models have positioned
SoxF genes both upstream (Corada et al., 2013) and downstream
(Lee et al., 2014) of Notch signalling in endothelial cells, suggesting
a complex relationship between these two pathways.
Analysis of the only known enhancers for the Notch pathway,
namely the arterial-specific Dll4-12 (Sacilotto et al., 2013) and
Dll4in3 enhancers (Sacilotto et al., 2013; Wythe et al., 2013), has
demonstrated a crucial role for SoxF factors in the regulation of
expression of the Notch ligand Dll4 in arteries, in combination with
Rbpj/Notch binding and in the presence of ETS factors including
Erg (Sacilotto et al., 2013; Wythe et al., 2013). Although this work
clearly positioned the SoxF and Notch pathways as crucial
regulators of arterial specification, and is supported by analysis
placing Sox17 upstream of Notch signalling in mouse models
(Corada et al., 2013), ablation of arterial marker expression only
occurs after the removal of both SoxF factors and Notch signalling
in combination (Sacilotto et al., 2013). Consequently, the precise
transcriptional hierarchy of SoxF and Notch has yet to be fully
established. Although studies of the Notch receptor genes Notch1
and Notch4 also identified SoxF binding motifs within putative
promoter sequences (Corada et al., 2013; Lizama et al., 2015), a
requirement for these SoxF motifs in arterial-specific gene
expression of Notch receptors has not been established. In this
study, we have identified and characterised arterial-specific
enhancers directing NOTCH1/notch1b gene expression in vivo,
and used them to demonstrate a direct requirement for SoxF factors
in the transcriptional regulation of Notch receptors during early
arterial differentiation, positioning SoxF factors upstream of Notch
in the acquisition of arterial cell identity.
RESULTS
Identification of an arterial-specific NOTCH1 intronic
enhancer
Previous studies into the transcriptional regulation of the Notch
receptors have not extended to the identification or analysis of gene
enhancers (cis-regulatory elements) (Corada et al., 2013; Lizama et al.,
2015; Wu et al., 2005). We therefore conducted a detailed in silico
analysis of the NOTCH1 locus with the aim of identifying novel,
arterial-specific enhancers. This analysis focused on humanNOTCH1
in order to take advantage of the wealth of publicly available
information describing chromatin modifications in human endothelial
cell lines. Using this information, we were able to pinpoint four
regions of DNA rich in endothelial cell-specific H3K4me1 and
H3K27ac histone modifications and DNaseI digital genomic
footprints, all marks closely associated with enhancer activity
(Heintzman and Ren, 2009; Sabo et al., 2004) (Fig. 1A, Fig. S1).
The putative enhancer regions were named NOTCH1+33,
NOTCH1+16, NOTCH1+3/5 and NOTCH1−68 to reflect their
distance from the transcription start site (TSS) in kb. Each enhancer
region was cloned upstream of the silent hsp68 minimal promoter
Fig. 1. The humanNOTCH1 locus AQ31
¶
containsmultiple putative endothelial enhancers. (A) The humanNOTCH1 locus fromUCSCENCODEGenomeBrowser
(http://genome.ucsc.edu). Human umbilical vein endothelial cell (HUVEC)-specific H3me1 and H3K27ac (enhancer associated) and H3K4me3 (promoter
associated) peaks are indicated in light blue [both in the separate HUVEC and combined tracks (denoted as ‘all’)]; other colours indicate H3K4me1, H3K4me3 and
H3K4ac peaks specific to non-endothelial cell lines: GM12878 cells (red), H1-hESC cells (yellow), HSMM cells (green), K562 cells (purple) NHEK cells (lilac) and
NHLF cells (pink). INPP5E and SEC16A are shown (blue text) in addition to NOTCH1 (black text). DNase I digital hypersensitive hotspots are indicated by black
vertical lines on grey (HUVEC, HMVEC-dBl-Ad, HMVEC-dBl-Neo and HMVEC-LBl, which are all different endothelial cell types). The four NOTCH1 putative
enhancer regions (black bars) were identified by high levels of HUVEC-specific H3K4me1 and H3K27ac associated with endothelial cell-specific DNaseI
hypersensitivity hotspots. P, putative promoters identified by H3K4me3. (B) The human NOTCH1 gene (top, in 5′ to 3′ orientation with putative enhancers
indicated) and the NOTCH1+16hsp transgene (bottom).
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and the lacZ reporter gene (Fig. 1B) and tested for its ability to drive
reporter gene expression specifically in arterial endothelial cells of
transient transgenic mice at embryonic day (E) 12-13. Although
each of the four putative enhancer regions was able to drive
detectable levels of lacZ in transgenic mice, this expression was
primarily neural, an expression pattern commonly seen when using
the hsp68 minimal promoter (e.g. Becker et al., 2016; Sacilotto
et al., 2013) (Table 1AQ6
¶
, Fig. S2). Only the NOTCH1+33 and
NOTCH1+16 enhancers were able to direct expression in
endothelial cells (Table 1AQ7
¶
, Fig. S2). In the case of NOTCH1+33,
vascular expression was detected in only one of the five transgenic
mice analysed. This expression was not restricted to the arterial
endothelium but was pan-endothelial (Table 1AQ8
¶
, Fig. S2). This agrees
with previous reports indicating that the mouse orthologue of this
region, termed Notch1_enh1, also directs occasional vascular
enhancer activity but did not show arterial-specific expression
(Zhou et al., 2017). Conversely, the 274 bp NOTCH1+16 enhancer
was able to robustly direct expression specifically to arterial
endothelial cells within the vasculature at E12 in multiple
independent transgenic embryos (Table 1AQ9
¶
, Fig. 2 and Fig. S2).
This indicates that the NOTCH1+16 enhancer represents a novel,
arterially restricted enhancer within the NOTCH1 locus. Analysis of
a stable mouse line expressing the NOTCH1+16:lacZ transgene
clearly demonstrated that this enhancer is strongly active from the
very early stages of vascular development, mimicking the
expression of endogenous Notch by becoming restricted to the
arteries by late E9.5 and then maintaining an arterial endothelial
cell-restricted expression pattern throughout embryonic
development (Chong et al., 2011; Jahnsen et al., 2015) (Fig. 2).
The NOTCH1+16 enhancer is bound and regulated
by SoxF factors
To identify the transcription factors that potentially regulate the
NOTCH1+16 enhancer, we performed a ClustalW analysis of
orthologous mammalian sequences (Fig. 3A). This analysis clearly
identified nine conserved core consensus ETS binding motifs [GGAW
(Hollenhorst et al., 2011)] and two consensus SOXAQ10
¶
binding motifs
[WWCAAW (Mertin et al., 1999)] (Fig. 3A) within the 274 bp
NOTCH1+16 enhancer. Because not all in silico consensus binding
motifs are able to functionally bind the cognate protein, these motifs
were then tested by electrophoretic mobility shift assay (EMSA). Both
SoxF motifs (termed hmSOX-a and hmSOX-b) were able to bind
recombinant SOX7 and SOX18 proteins in EMSA (Fig. 3B), and three
ETS motifs (termed hmETS-a, hmETS-b and hmETS-c) were able to
bind the endothelial ETS protein ETV2 (Fig. 3C).
ETS motifs are common to all endothelial-expressed gene
enhancers (De Val and Black, 2009). Although the ETS factor Erg
has been implicated in arterial specification (Wythe et al., 2013),
previous studies have shown that ETS motifs were unable to direct
expression of the arterial-specific Dll4 and Flk1 enhancers without
additional transcription factor binding motifs (Becker et al., 2016;
Sacilotto et al., 2013;Wythe et al., 2013), suggesting that ETS factors
alone are unlikely to regulate the NOTCH1+16 enhancer.
To test whether the SoxF motifs play a role in NOTCH1+16
enhancer activity, we mutated the core nucleotides of these motifs
(see Materials and Methods for sequences) and tested the ability of
the resultant NOTCH1+16mutSOX-a/b enhancer to drive reporter
gene expression. Strikingly, enhancer mutation resulted in a
dramatic reduction in reporter gene expression in endothelial cells
in transgenic mice, although transgene expression was detected
outside of the vascular system (Fig. 4, Table 1 AQ11
¶
). This result differs
notably from that reported for the Dll4 enhancers, where mutations
in SoxF motifs, or loss of SoxF factors, resulted in no detectable
decrease in Dll4 expression unless accompanied by ablation of
Notch signalling (Sacilotto et al., 2013).
Zebrafish notch1b is directly transcriptionally regulated by
SoxF factors via an evolutionarily non-conserved enhancer
The SoxF-dependent NOTCH1+16 enhancer robustly directed
arterial-restricted expression in transgenic mouse models. However,
this enhancer did not exhibit sequence conservation beyond
Table 1.AQ39
¶
Reporter gene expression patterns in E12 mice transgenic for
each putative NOTCH1 enhancer region and the effects of SoxF motif
mutation on NOTCH1+16 enhancer activity
TAQ22
¶
ransgene n
Any lacZ
expression
lacZ in
AECs
lacZ in
VECs
NOTCH1−68 5 3 0 0
NOTCH1+3/5 4 4 0 0
NOTCH1+16 10 9 6 0
NOTCH1+33 5 5 1 1
NOTCH1+16 WT 8 7 4 0
NOTCH1+16mutSOX-a/b 9 6 0* 0*
*Faint vascular expression was detected in section analysis but was not visible
in whole-mount analysis. n, number of transgenic mice analysed. AECs,
arterial endothelial cells; VECs, venous endothelial cells.
Fig. 2. The NOTCH1+16 transgene directs arterial endothelial cell-
restricted expression in transgenic mice. (A-N) Representative transgenic
whole-mount embryos (A-H) and transverse sections (I-N) showing lacZ
reporter gene expression (β-galactosidase detected by blue X-gal staining) in
arterial endothelial cells throughout embryonic development. The boxed region
in J is magnified in K. (O,P) E12 transverse section showing that expression of
the venous marker endomucin (Emcn) does not overlap with lacZ reporter
gene expression on the same section. cv, xxxxxx xxxxxx; da, xxxxxx xxxxxx;
en, xxxxxx xxxxxx; mda, xxxxxx xxxxxx; uv, xxxxxx xxxxxx; v, xxxxxx xxxxxx.
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mammals (Fig. S1B), leaving it unclear how relevant these
observations are to Notch signalling during arteriovenous
specification in zebrafish, an extremely well-studied model system
(Gore et al., 2012). We therefore investigated whether SoxF factors
were able to transcriptionally regulate the zebrafish orthologue of
NOTCH1, notch1b, by examining the binding patterns of the
zebrafish SoxF transcription factors around the notch1b locus.
Zebrafish SoxF are expressed in early endothelial cells and
implicated in arteriovenous differentiation (Cermenati et al., 2008;
Hermkens et al., 2015; Herpers et al., 2008; Pendeville et al., 2008).
To probe for SoxF (Sox7, Sox17 and Sox18) genome-wide binding
locations we used an endothelial-specific SOX18Ragged
overexpression line. The SOX18Ragged dominant-negative
protein has been shown to interfere with the endogenous function
of all three SoxF transcription factors (xxxxx citation? xxxxx).
Using 26-28 hours post fertilisation (hpf ) embryos from the tg
(fli1a:Gal4FF;10×UAS:Sox18Ragged-mCherry) zebrafish line, in
which a tagged SOX18Ragged is expressed specifically in
endothelial cells (Fig. S3A), ChIP-seq analysis identified a SoxF
binding event 15 kb upstream of the notch1b first exon (Fig. 5A).
This binding peak was enriched in the enhancer-associated histone
modifications H3K4me1 and H3K27ac at 24 hpf (Bogdanovic ́
et al., 2012; Kent et al., 2002) (Fig. 5A), suggesting that it might
represent a novel enhancer of notch1b. A 1219 bp zebrafish DNA
fragment corresponding to the SOX18-bound region, termed the
notch1b-15 enhancer, was cloned upstream of a silent gata2a
promoter and GFP reporter gene within the zebrafish enhancer
detection (ZED) vector (Bessa et al., 2009) (Fig. 5B) and used to
generate the stable tg(notch1b-15:GFP) fish line (Fig. 5C). The
GFP transcript was detected in the vascular cord around the midline
from 19 hpf, and persisted in the vascular rod as it formed the dorsal
aorta at 22 hpf (Fig. 5C). GFP expression continued to be restricted
to the dorsal aorta and the segmental arteries in larvae from 24 hpf
until 48 hpf. This arterial-restricted pattern of expression within the
vasculature was similar to that of endogenous notch1b (Fig. S3B),
indicating that the SOX18-bound notch1b-15 element is a bona fide
notch1b enhancer and suggesting that SoxF factors directly
transactivate Notch receptor transcription in arterial endothelial
cells in zebrafish.
ClustalW analysis comparing the orthologous enhancer
sequences from fugu, stickleback and medaka revealed a
remarkably similar pattern of conserved transcription factor motifs
when compared with the NOTCH1+16 enhancer (Fig. 6A), with
multiple ETS and two S AQ12
¶
OX binding motifs, termed zfSOX-a and
zfSOX-b, confirmed by EMSA analysis (Fig. 6B,C). To establish
whether the zfSOX-a and zfSOX-b binding motifs were required for
notch1b-15 arterial enhancer function, we generated transient
transgenic fish lines harbouring mutated S AQ13
¶
OX binding motifs
(notch1b-15mutSOX-a/b:GFP) and compared the activity of the
transgene with wild-type (WT) notch1b-15:GFP control transient
transgenic animals (Fig. S4A,B). Simultaneous disruption of both
zfSOX-a and zfSOX-b sites led to a reduction of arterial-specific
GFP expression in endothelial cells. Although a minority of mutant
fish still expressed GFP after SoxF binding site mutation, the loss of
expression was still much greater than that seen after SoxF motif
mutation in a previously published Dll4 enhancer in transgenic
zebrafish, where vascular expression rates were unaffected by
S AQ14
¶
OXFa/b mutation (Sacilotto et al., 2013), supporting a key role for
SoxF factors in notch1b activation. To further confirm our
observation, we established stable transgenic notch1b-15mutSOX-
a/b:GFP fish lines and compared them with the established WT
notch1b-15:GFP lines. Analysis of the stably transgenic embryos
(Fig. 7A) confirmed a GFP expression pattern in the dorsal aorta
and segmental arteries for the WT transgene. By contrast, the tg
Fig. 3. The NOTCH1+16 enhancer contains SoxF and ETS binding motifs.
(A) Multispecies alignment of the orthologous region of the NOTCH1+16
enhancer from human, mouse and opossum (oposs) using ClustalW. Coloured
sequences are confirmed by EMSA; grey sequences are motifs identified
in silico that did not bind in EMSA. (B) Radiolabelled oligonucleotide probes
encompassing NOTCH1+16 hmSOX-a (lanes 1-8) and hmSOX-b (lanes 9-16)
were bound to recombinant SOX7 (lanes 2-4 and 10-12) and SOX18 (lanes 6-8
and 14-16). Both proteins, which efficiently bound labelled probes (lanes 2,
6, 10 and 14), were competed by excess unlabelled self-probe (WT, lanes 3, 7,
11 and 15) but not by mutant self-probe (MT, lanes 4, 8, 12 and 16).
(C) Radiolabelled oligonucleotide probes encompassing NOTCH1+16 hmETS-
a (lanes 17-20), hmETS-b (lanes 21-24) and hmETS-c (lanes 25-28) were
bound to recombinant ETV2 protein. ETV2, which efficiently bound to
labelled probes (lanes 18, 22 and 26), was competed by excess unlabelled self-
probe (WT, lanes 19, 23 and 27) but not by mutant self-probe (MT, lanes
20, 24 and 28).
Fig. 4. SoxF factors are required for NOTCH1+16 activity. (A) Four
representative whole-mount E12 X-gal-stained embryos transgenic for the
NOTCH1+16mutSOX-a/b construct. Numbers at the bottom left indicate the
unique embryo identifier. (B AQ32
¶
) Transverse sections taken from two NOTCH1
+16mutSOX-a/b embryos demonstrate the very limited endothelial expression
detected in these embryos (asterisks).
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(notch1b-15mutSOX-a/b:GFP) lines showed ectopic GFP
expression in neurons and a significant decrease of GFP
expression in the arterial endothelium (Fig. 7A). Quantitative
analysis of GFP intensity in both dorsal aorta and segmental arteries
showed lower expression in most tg(notch1b-15mutSOX-a/b:GFP)
than in WT tg(notch1b-15:GFP) embryos (Fig. 7B,C, Fig. S4C).
Taken together, these data clearly demonstrate that the zfSOX-a/b
binding sites are required to guide notch1b-15-specific enhancer
activity in vivo during arterial development.
We next investigated the consequences of morpholino (MO)-
based knockdown of SoxF on tg(notch1b-15:GFP) fish. sox7/sox18
double morphants exhibit a severe vascular phenotype (Fig. S5),
including fusions and shunts between the dorsal aorta and cardinal
vein (Cermenati et al., 2008; Herpers et al., 2008; Pendeville et al.,
2008), phenotypes that are shared with sox7;sox18 double-mutant
fish (Hermkens et al., 2015). MO-induced transcript depletion of
sox7 or sox18 resulted in downregulation of notch1b-15:GFP
expression, while sox7/sox18 double-morphant tg(notch1b-15:
GFP) fish demonstrated a near-complete loss of reporter gene
expression (Fig. 7D,E).
Taken together, these results indicate that SoxF proteins directly
modulate the activity of arterial-specific enhancers for both the
mammalian NOTCH1 and zebrafish Notch1b receptors, positioning
SoxF transcription factors directly upstream of Notch signalling
during early arterial differentiation in both mammals and zebrafish.
Loss of endogenous notch1b-15 enhancer activity perturbs
notch1b transcription and causes arteriovenous defects
To assess whether the endogenous notch1b-15 regulatory element is
functionally relevant during arteriovenous differentiation in vivo, we
deleted the endogenous notch1b-15 enhancer in zebrafish. The
resultant notch1b-15uq1mf allelewas generated using two guide RNAs
to drive rapid genome editing using the CRISPR/Cas9 system
(Fig. 8A), resulting in excision of a 203 bp fragment overlapping the
notch1b-15 enhancer. Analysis of endogenous notch1b expression in
the F2 generation demonstrated lower notch1b expression levels in
both dorsal aorta and arterial intersomitic vessel (aISV) of the
notch1b-15uq1mf/uq1mf homozygous embryos as compared with their
sibling controls, whereas no change was observed in the neural tube
(Fig. 8B). Next, we assessed the notch1b transcript levels in purified
flt1-positive arterial endothelial cell populations from the F3
Fig. 5. A SOX18-bound regionwithin the notch1b locus represents a bona
fide arterial-specific enhancer. (AAQ33
¶
) Part of the zebrafish notch1b locus from
the UCSC ENCODE Genome Browser. The notch1b gene is in 3′ to 5′
orientation, H3K27ac peaks at 24 hpf are in purple, H3K4me1 peaks at 24 hpf
are blue, SOX18Ragged ChIP-seq peaks are red, and the region
encompassing the notch1b-15 enhancer is indicated by the purple horizontal
bar. (B) The ZED notch1b-15:GFP transgene. Ins, insulator sequences;
GATA2 prom, the silent GATA2 promoter; ZED control:RFP, the active cardiac
actin enhancer/promoter construct fused to the RFP gene used as a positive
control in the ZED vector. (C) The notch1b-15:GFP transgene directs arterial
endothelial cell-specific expression in the zebrafish line tg(notch1b-15:GFP).
Representative transgenic whole-mount embryos and transverse sections
show reporter gene expression, as detected by in situ hybridisation (top row,
blue) or GFP fluorescence (bottom rows, green) in arterial endothelial cells
throughout embryonic development. nt, neural tube; nc, notochord; DA, dorsal
aorta; PCV, posterior cardinal vein; aISV (arrows), arterial intersomitic vessel;
DLAV, dorsal longitudinal anastomotic vessel.
Fig. 6. The notch1b-15 enhancer contains essential SoxF binding motifs.
(A) Multispecies alignment of the orthologous regions of the notch1b-15
enhancer from zebrafish (zfish), fugu, stickleback (stickle) and medaka using
ClustalW. Coloured sequences are confirmed by EMSA; grey sequences are
motifs identified in silico that did not bind robustly in EMSA. (B) Radiolabelled
oligonucleotide probes encompassing notch1b-15 zfSOX-a (lanes 1-8) and
zfSOX-b (lanes 9-16) were bound by recombinant SOX7 (lanes 2-4 and 10-12)
and SOX18 (lanes 6-8 and 14-16). Both proteins, which efficiently bound
labelled probes (lanes 2, 6, 10 and 14), were competed by excess unlabelled
self-probe (WT, lanes 3, 7, 11 and 15) but not bymutant self-probe (MT, lanes 4,
8, 12 and 16). (C) Radiolabelled oligonucleotide probes encompassingnotch1b-
15 z AQ34
¶
fETS-a (lanes 17-20) and zfETS-b (lanes 21-24) (see A) were bound by
recombinant ETV2 proteins. ETV2, which efficiently bound to labelled probes
(lanes 18 and 22), was competed byexcess unlabelled self-probe (WT, lanes 19
and 23) but not by mutant self-probe (MT, lanes 20 and 24).
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generation of homozygous fish (F2 notch1b-15uq1mf homozygous in-
cross) compared with WT control larvae (F2 notch1b-15+/+ × flt1:
YFP;lyve1:dsRed) at 24-28 hpf (Fig. 8C). As expected, notch1b
transcripts were significantly downregulated in the homozygous
animals, strongly supporting a role for the notch1b-15 enhancer in the
transcription of endogenous notch1b in arterial endothelial cells.
To assess the phenotypic outcome of notch1b-15 loss of function,
we took advantage of the tg(notch1b-15uq1mf/+;flt1:YFP;lyve1:
dsRed) line to analyse the developing vasculature after notch1b-15
enhancer deletion in both the F2 and F3 generations. Surprisingly,
given the reduced levels of notch1b (Fig. 8B), no overt vascular
phenotype was detected in F2 notch1b-15uq1mf/uq1mf homozygous
zebrafish (F1 homozygous in-cross) (Fig. S6A), suggesting partial
enhancer redundancy. Such redundancy, which is potentially
explained by the pervasiveness of redundant, or ʻshadow’,
enhancers around developmental genes (Cannavò et al., 2016), has
previously been well documented in key endothelial genes, with
examples including the Dll4, Flk1 and Tal1 loci (Cannavò et al.,
Fig. 7. SoxF factors are required for notch1b-15 activity. (A) Confocal
projection of stably transgenic WT tg(notch1b-15:GFP) (left) and tg(notch1b-
15mutSOX-a/b:GFP) (right), where both zfSOX-a and zfSOX-b sites have
been simultaneously mutated. Representative larvae from four independent
founders are shown. Asterisks indicate the reduced GFP expression in the
dorsal aorta. Arrowheads show the ectopic neuronal expression observed in tg
(notch1b-15mutSOX-a/b:GFP). AAQ35
¶
ll panels show composite images. (B,C) The
intensity of GFP expression in the dorsal aorta and arterial intersomitic vessels
of the stably transgenic tg(notch1b-15:GFP) and tg(notch1b-15mutSOX-a/b:
GFP) at 2 dpf. Expression is normalised to GFP genomic copy number. Fish
were pooled from three or four separate founders. Mean±s.e.m. tg(notch1b-
15), n=41; tg(notch1b-15mutSOX-a/b:GFP), n=29. ****P<0.0001 (Mann–
Whitney U-test). (D) Levels of GFP expression in tg(notch1b-15:GFP)
zebrafish embryos after MO injection. Number of fish for each condition is
indicated. (E) Representative examples of sox7/18 double-morphant tg
(notch1b-15:GFP) zebrafish at 24 hpf as compared with uninjected controls.
Double morphants (dMO) demonstrated reduced EGFP expression in the
dorsal aorta and intersomitic vessels. DA, dorsal aorta; PCV, posterior cardinal
vein; aISV, arterial intersomitic vessel.
Fig. 8. Loss of endogenous notch1b-15 compromises artery formation
and reduces the endogenous notch1b transcript level. (A) The deleted
region (dashed line) of notch1b-15 mutant allele uq1mf, which includes both
the zfSOX-a and zfSOX-b sites (yellow). (B) F2 notch1b-15uq1mf/uq1mf has
reduced notch1b expression in dorsal aorta and intersomitic vessels (white
arrows) as compared with sibling WT and heterozygotes (black arrows) at 26-
28 hpf. The number of embryos showing the illustrated phenotype among the
total examined is indicated. (C) Quantitative PCR on FACS-sorted endothelial
populations at 24-28 hpf, showing that F3 notch1b-15uq1mf/uq1mf fish have lower
notch1b expression thanWT fish. Expression is relative to kdrl and flt1. Mean±
s.e.m. n=6 (uq1mf/uq1mf ) and n=8 (WT) independent sorts, where each sort
was pooled from 60-100 larvae;. *P<0.05, ***P<0.001 (t-test). (D) The
treatment regime conducted to characterise the vascular phenotype of the
u AQ36
¶
q1mf/+ cross. In treatment 1 (T1, red), notch1bMOwas injected at the 1-2 cell
stage. The developing vasculature of each embryo was then analysed blindly at
3 dpf. After scoring, genotypes were assigned to each larva. In treatment 2 (T2,
blue), larvae from the uq1mf/+ cross were treated with or without DAPT (5 µM)
from 15-16 hpf until 3 dpf. Vessels of these treated larvae were blindly scored
prior to genotyping, as reported for T1. (E) At 3 dpf, notch1b-15uq1mf/uq1mf
notch1b morphants frequently showed ectopic sprouting in between the
intersomitic vessels (asterisks) as compared with sibling WT notch1b
morphants. Mutants also show loss of arterial connections (red arrowheads)
between the dorsal longitudinal anastomotic vessel (DLAV) and dorsal aorta
(DA), as indicated by the loss of YFP expression in the tg(flt1:YFP) background.
(F) (Top) Quantification of hypersprouting ISV number in individual notch1b
morphants labelled by tg(flt1:YFP) at 3 dpf. Mean±s.e.m. Sibling WT (+/+),
n=20; heterozygote (uq1mf/+), n=32; homozygous mutant (u AQ37
¶
q1mf/uq1mf ),
n=21. (Bottom) Quantification of YFP-positive intersomitic vessels that connect
between DLAV and DA in individual notch1bmorphants labelled by tg(flt1:YFP)
at 3 dpf. Mean±s.e.m. Sibling WT, n=20; heterozygote, n=32; homozygous
mutant, n=21. **P<0.005 (Mann–Whitney U-test). (G) Quantification of YFP-
positive intersomitic vessels that connect between DLAV and DA in individual
embryos treated with 5 μM DAPT at 3 dpf. Vessels are labelled by tg(flt1:YFP).
Mean±s.e.m. Sibling WT, n=9; heterozygote, n=25; homozygous mutant, n=14.
*P<0.05 (Mann–Whitney U-test).
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2016). By contrast, we detected a subpopulation (20-30%) of larvae
from the F3 generation (F2 homozygous notch1b-15uq1mf/uq1mf in-
cross) that displayed a phenocopy of the notch1b loss-of-function
phenotype (Fig. S6B). This increase in the pAQ15
¶
henotypic outcome in the
F3 generation suggests that, in the context of the notch1b-15uq1mf/+
cross, maternal mRNA deposition is likely to help compensate for
the disruption of notch1b transcription caused by deletion of the
notch1b enhancer, a compensation that is reduced in a purer notch1b-
15uq1mf/uq1mf genetic background (Harvey et al., 2013).
To bypass potential rescue effects of shadow enhancers or
maternally deposited transcripts, we also investigated
arteriovenous differentiation and sprouting angiogenesis in F2
notch1b-15uq1mf/uq1mf zebrafish after low-level depletion of notch1b
mRNA. A splice notch1b MO was injected into eggs from a
notch1b-15uq1mf/+ in-cross in the tg(flt1:YFP;lyve1:dsRed)
background. The notch1b MO was used at suboptimal
concentration (5 ng/embryo), which is known to result in minimal
phenotypes (Sacilotto et al., 2013). The developing vasculature of
each resulting embryo was analysed blindly at 3 dpf, and genotypes
were assigned to embryos after image acquisition (Fig. 8D, red).
Whereas most WT siblings had normal ISV development, we
observed an increased number of hypersprouting ISVs across the
notch1b-15uq1mf/+ and notch1b-15uq1mf/uq1mf population (Fig. 8E,
asterisks; Fig. 8F, top) in a gene dosage-dependent manner, similar
to the phenotype described previously in high MO concentration
notch1b morphants and Notch signalling-deficient embryos
(Geudens et al., 2010; Siekmann and Lawson, 2007). Further,
mutant embryos also demonstrated loss of arterial connections
between the dorsal aorta and dorsal longitudinal anastomotic vessel,
similar to those described in Notch signalling-deficient zebrafish
(Geudens et al., 2010; Quillien et al., 2014), while the notch1b-
depleted notch1b-15+/+ and notch1b-15uq1mf/+ morphantAQ16
¶
embryos
demonstrated an equal proportion of arterial and venous ISVs as
previously reported (Bussmann et al., 2010) (Fig. 8E,F bottom).
To further confirm that interfering with notch1b-15 enhancer
activity is additive to notch1b transcript depletion, we chemically
treated the notch1b-15uq1mf/+ cross with DAPT, a well characterised
Notch signalling inhibitor, over the course of endothelial
differentiation (15- to 16-somite stage through to 3 dpf) (Fig. 8D,
blue). All embryos treated with a suboptimal concentration of
DAPT (5 µM) showed a straight body axis, indicating that
somitogenesis (and therefore Notch activity) was not significantly
compromised (Fig. S7A). Interestingly, despite this lack of
morphological defects, F2 fish homozygous for the notch1b-
15uq1mf allele displayed a lower arterial-to-total ISV ratio (Fig. 8G,
Fig. S7A). By contrast, fish homozygous for the notch1b-15uq1mf
allele treated with DMSO vehicle alone had a comparable aISV ratio
to both notch1b-15+/+ and notch1b-15uq1mf/+ siblings (Fig. S7B),
similar to the untreated control. This suggests that the observed loss
of aISV is specific to an additive effect of DAPT treatment and
notch1b-15 enhancer activity disruption. Overall, these data suggest
a functional role of the notch1-15 enhancer in the endothelial-
specific initiation of notch1b transcription to promote the
acquisition of arterial cell identity.
SoxF factors are required for endogenous Notch1/notch1b
expression
Our results have clearly implicated SoxF factors as direct upstream
regulators of arterial Notch enhancers, and therefore suggest a
considerably greater role for SoxF aAQ17
¶
lone in the regulation of the
Notch receptors than in the Notch ligands. However, since the
notch1b-15 enhancer is partially redundant with xxxxx xxxxx
xxxxx?, we wished to establish whether SoxF regulation is required
for endogenous notch1b expression itself, not just enhancer activity.
Further, our results so far do not entirely rule out the possibility of
SoxF/Rbpj combinatorial regulation of notch1b, as was previously
shown for Dll4 enhancers (Sacilotto et al., 2013). Although neither
the human NOTCH1+16 nor the zebrafish notch1b-15 enhancer
contains conserved consensus Rbpj/Notch binding motifs,
transcription factors can bind non-consensus motifs, and not all
transcription factors necessarily bind conserved motifs (Wong et al.,
2015). The nature of the SoxF/Notch combinatorial regulation of
Dll4, where the SoxF or Rbpj binding motifs play functionally
interchangeable roles, indicates potential direct interactions between
these two proteins, such that only a single SoxF binding motif might
be necessary for SoxF/Rbpj synergy. We therefore investigated the
consequences of SoxF depletion on endogenous Notch1/notch1b
expression in vivo.
Although Sox17 is robustly expressed in arterial endothelial cells
(Corada et al., 2013; Hosking et al., 2009), compound Sox7;Sox18
deletion in mice resulted in a reduction of Notch1 mRNA levels in
the trunk dorsal aorta and primitive heart cavities of E8.5 embryos
(Fig. 9A, Fig. S8A). These results concur with observations in the
mouse retina, where the vascular phenotype after Sox7;Sox17;
Sox18 endothelial-specific triple deletion closely resembled defects
caused by loss of Notch signalling (Zhou et al., 2015). Strikingly,
both MO-induced gene knockdown and compound mutation of
sox7 and sox18 in zebrafish embryos also led to a near-complete
loss of notch1b transcript expression specifically in endothelial
cells, as shown by in situ hybridisation analysis (Fig. 9B,C,
Fig. S8B). These results further establish an essential role for SoxF
transcription factors in the induction of Notch1/notch1b gene
expression, and position SoxF proteins at the top of the
transcriptional hierarchy regulating arterial specification.
DISCUSSION
Recent work has implicated SoxF, ETS and Rbpj, the Notch
transcriptional effector, in the regulation of the Notch ligand Dll4
and many other key arterial genes (Corada et al., 2013; Lizama et al.,
2015; Sacilotto et al., 2013; Wythe et al., 2013), but has not
established the hierarchical arrangement of these diverse factors in
arterial specification and differentiation. In this study, we
demonstrate that arterial expression of the Notch receptor Notch1/
notch1b, a key player in arterial specification, is directly
downstream of SoxF regulation in both fish and mouse. Unlike
other key arterial specification markers, including Dll4, Efnb2a and
Dlc (Sacilotto et al., 2013), ablation of Notch1/Notch1b expression
after depletion of SoxF factors occurred without concurrent
inhibition of Notch signalling. Therefore, this work positions
SoxF factors directly above Notch signalling in the transcriptional
hierarchy initiating arterial development, and suggests that SoxF
factors might initiate a feed-forward loop directing arterial identity.
In this model, SoxF factors would first activate Notch signalling via
the transcriptional activation of Notch receptors in combination
with weak activation of Notch ligands (Sacilotto et al., 2013). This
early SoxF-mediated activity would then be boosted by the
initiation of Notch signalling, resulting in the sustained activation
of other downstream genes, eventually activating the full cohort of
genes necessary to acquire and maintain arterial endothelial cell
identity.
Understanding the function of SoxF factors through mutational
analysis has presented significant challenges. Strain-specific
variations in mice after depletion of individual SoxF genes and
varying levels of compensation from other SoxF factors have
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resulted in some contradictory reports (Corada et al., 2013; Lee
et al., 2014), as is also the case for zebrafish morphant analysis
(Cermenati et al., 2008; Herpers et al., 2008; Pendeville et al.,
2008). Nonetheless, the results described here agree with an
increasingly convincing body of work suggesting that SoxF factors
influence Notch signalling yet are unaffected by Notch ablation. For
example, overexpression of Sox17 upregulates components of the
Notch pathway (Corada et al., 2013; Lizama et al., 2015), loss of
functional SoxF factors results in defects similar to those observed
after Notch inhibition in mice and fish (Corada et al., 2013;
Sakamoto et al., 2007; Zhou et al., 2015), while Notch ablation
results in little alteration to the endothelial expression of SoxF
factors in mice and fish (Abdelilah et al., 1996; Corada et al., 2013).
Data reported here combine with these reports to strongly support a
role for SoxF factors as part of the initial transcriptional machinery
that instructs arterial specification events.
However, some questions remain. In particular, it is notable that
sox7;sox18 double-mutant fish, although exhibiting severe
arteriovenous defects very similar to those seen in Notch-
deficient fish (Lawson et al., 2001), do not fully recapitulate the
effects of Vegfa depletion on arterial specification (Lawson et al.,
2002). While this difference may in part be attributed to weak
expression of zebrafish sox17, which is expressed in some arterial
endothelial cells (Hermkens et al., 2015), it is also expected that
the Vegfa pathway has a wider effect on arterial endothelial cells
more generally, away from SoxF-mediated activation of Notch
signalling. SoxF factors are also influenced by signalling pathways
beyond Vegfa. The diverse nature of Vegfa roles in the
vasculature, including the regulation of both sprouting
angiogenesis and arteriogenesis, processes that inevitably
involve different cohorts of downstream targets, make it
necessary that multiple regulatory pathways interact with Vegfa
during vascular development. While recent work has shown that
Vegfa signalling increases the nuclear translocation of SoxF
(Duong et al., 2014), and inhibition of Vegfa results in the loss of
vascular sox7 in fish, sox18 is still expressed in the absence of
intact Vegfa signalling (Pendeville et al., 2008). Additionally, loss
of the Vegf co-receptor Nrp1 has little effect on SoxF expression in
mouse retinal vasculature (Zhou et al., 2015), pointing to other
upstream influences on SoxF function in endothelial cells. Other
upstream effectors of SoxF function are likely to include canonical
Wnt signalling and Vegfd, both of which have been shown to
i AQ18
¶
nfluence SoxF factors (Corada et al., 2013; Duong et al., 2014;
Zhou et al., 2015).
Recent evidence has also implicated a role for a coordinated
Vegf-Mapk-Ets pathway in the induction of Notch signalling
components and early arterial differentiation (Wythe et al., 2013).
Notably, in addition to SoxF motifs, both the Notch1 and Dll4
enhancers share a number of highly conserved consensus motifs
for the ETS family of transcription factors. While ETS motifs are
common to all vascular enhancer elements, including many that
are not preferentially expressed in the arterial vasculature (De Val
and Black, 2009), the ETS factor Erg has been specifically
implicated in arterial-specific regulation of Dll4 (Wythe et al.,
2013). It is therefore likely that Vegfa-mediated activation of
ETS factors may contribute to the transcriptional activity of
Notch downstream effectors, and thus may influence arterial
establishment independently of SoxF factors. However, it is
notable that Vegfa-mediated E AQ19
¶
TS transcription does not appear to
be sufficient for arterial gene expression. Dll4 enhancers lacking
SoxF and Rbpj motifs but retaining all ETS motifs were unable to
drive any transgene expression (Sacilotto et al., 2013), nor were
Notch enhancers lacking SoxF motifs (Figs 2–4). Similar results
were found in other delineated arterial enhancers, including the
Ece1 upstream enhancer (Robinson et al., 2014) and the Flk1
intron 10 enhancer, where loss of Rbpj-mediated repression
resulted in expansion of enhancer activity into venous cells
without alterations to ETS motif binding (Becker et al., 2016).
Combined with recent observations demonstrating that Erg also
plays a crucial role in venous specification through activation of
Aplnr (Lathen et al., 2014), it is therefore likely that the role of Erg,
and of other ETS factors, downstream of Vegfa in arterial-
restricted gene expression occurs in co-operation with a AQ20
¶
dditional
essential, arterial-specifying transcription factors. The data
presented in this work, combined with the analysis of further
arterial enhancers, including those of Dll4 and Ece1 (Robinson
et al., 2014; Sacilotto et al., 2013; Wythe et al., 2013), increasingly
suggest that SoxF may fulfil this role.
Fig. 9. Mouse and zebrafish arterial Notch1 expression is dependent on
SOX7/18 activity. (AAQ38
¶
) Transverse sections of whole-mount in situ hybridisation
for Notch1 transcript on E8.5 mouse embryos shows a reduction of Notch1
expression (asterisks) in the bulbus cordis (bc) region of the primitive heart and
vitelline artery (va) of Sox7/Sox18 double knockouts. (B) At 24 hpf notch1b
expression is significantly downregulated in the dorsal aorta (asterisks) of
sox7/sox18 double-morphant zebrafish, whereas its signal is unaffected in the
neural tube. flt1 expression is comparable between controls and sox7/sox18
double morphants, indicating that the dorsal aorta is correctly formed. (C)
notch1b was barely detectable in the dorsal aorta and ISVs of sox7/18 double-
knockout zebrafish (asterisks), as compared with the WT, sox7 or sox18
heterozygotes (arrows). The number of embryos showing the illustrated
phenotype among the total examined is indicated. DA, dorsal aorta; PCV,
posterior cardinal vein.
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MATERIALS AND METHODS
Cloning
The 10×UAS:Sox18Ragged-mCherry plasmid was generated using the full-
length mouse Sox18Ragged cDNA sequence, tagged with 10×UAS and
mCherry and cloned into pDestTol2CG2 (xxx source? xxx). notch1b-15:GFP
WT was generated by cloning a 1219 bp PCR fragment from zebrafish
genomic DNA together with gata2a promoter andGFP reporter gene into the
zebrafish enhancer detection (ZED) vector (Bessa et al., 2009). notch1b-
15mutSOX-a/b was generated by site-directed PCR mutagenesis of the WT
construct. The NOTCH1−68, NOTCH1+3/5 and NOTCH1+33 enhancers
were generated by PCR from mouseAQ21
¶
genomic DNA, NOTCH1+16 WT and
NOTCH1+16mutSOX-a/b enhancers were generated as custom-made, double-
stranded linear DNA fragments (GeneArt Strings, Life Technologies). All
mammalian fragments were cloned into the hsp68-lacZ Gateway vector
(provided byN.Ahituv) (DeVal et al., 2004). Primers and sequences forDNA
fragments are listed in the supplementary Materials and Methods.
Transgenic animals and genome editing
Animal procedures were approved by local ethical review and licensed by the
UKHomeOffice or conformed to institutional guidelines of the University of
Queensland Animal Ethics Committee. Transgenic mice were generated by
oocyte microinjection and analysed as detailed in the supplementary
Materials and Methods (De Val et al., 2004). Compound Sox7−/−;Sox18−/−
(C57BL/6) mouse embryos were generated on the C57BL/6 background
through crossing heterozygous Sox7:tm1 to Sox18:tm1 generating Sox7+/−;
Sox18+/− mice, which were subsequently in-crossed (Pennisi et al., 2000a).
Transgenic zebrafish embryos were generated using the Tol2 system in
conjunction with the ZED vector (Bessa et al., 2009). The sox7hu5626;
sox18hu10320 double-homozygous mutant zebrafish have been described
previously (Hermkens et al., 2015). The tg(fli1a:Gal4FF,10×UAS:
Sox18Ragged-mCherry) zebrafish line was generated by crossing 10×UAS:
Sox18Ragged-mCherry with fli1a:Gal4FF, 4×UAS Utrophin GFP. MO-
mediated knockdown was performed as previously described (Herpers et al.,
2008). CRISPR genome editing for notch1b-15 was performed as described
by Gagnon et al. (2014) using the primers listed in the supplementary
Materials and Methods to generate notch1b-15uq1mf (203 bp deletion) allele.
The F2 notch1b-15uq1mf/uq1mfAQ23
¶
was generated by in-crossing notch1b-
15uq1mf/+, while F3 notch1b-15uq1mf/uq1mfwas generated from the F2 notch1b-
15uq1mf/uq1mf in-cross, both in the tg(flt1:YFP;lyve1:dsRed) background.
Chromatin immunoprecipitation (ChIP)
Positive tg(fli1a:Gal4FF;10×UAS:Sox18Ragged-mCherry) fish larvae were
collected at 26-28 hpf and treatedAQ24
¶
as previously described (Mohammed et al.,
2013). DNA amplification was performed using the TruSeq ChIP-seq Kit
(Illumina, IP-202-1012) following immunoprecipitation. The library was
quantified using the KAPA library quantification kit for Illumina sequencing
platforms (KAPA Biosystems, KK4824) and 50 bp single-end reads were
sequenced on a HiSeq 2500 (Illumina) following the manufacturer’s protocol.
FAQ25
¶
ASTQ files were mapped to GRCz10/danRer10 genome assembly using
bowtie (xxxxx citation? xxxxx), and peaks were called using MACS version
2.1.0. using input as a reference. To avoid false-positive peaks calling due to
the mCherry epitope, ChIP-seqwith the mCherry epitope only was performed
in parallel to SOX18Ragged-mCherry ChIP-seq and peaks called in these
experimental conditions were subtracted from the peaks called in the
SOX18Ragged-mCherry conditions. For details, see the supplementary
Materials and Methods.
Motif identification and EMSA
Sequences were analysed for consensus sequence motifs by eye and using
TRANSFAC (BIOBASE; www.biobase-international.com/transcription-
factor-binding-sitesAQ26
¶
) (Matys et al., 2006). EMSAs were performed as
previously described (De Val et al., 2004), as outlined in the supplementary
Materials and Methods.
Morpholinos and drug treatment
MO-mediated knockdown was performed as previously described (xxxxx
citation? xxxxx). ATGMOs against sox7 and sox18were injected into the tg
(notch1b-15:GFP) stable line at the 1-2 cell stage at 5 ng/embryo (Herpers
et al., 2008). To assess the effect of sox7/18 knockdown on endogenous
notch1b transcripts, sox7 and sox18 MOs were injected into WT zebrafish
larvae at 1 ng/embryo in parallel with a standard control MO (std-MO)
injected at 2 ng/embryo (Cermenati et al., 2008). To characterise notch1b-
15uq1mf, notch1b MO was injected into the notch1b-15uq1mf/+ cross at 5 ng/
embryo. For MO sequences, see the supplementary Materials and Methods.
N-[(3,5-difluorophenyl)acetyl]-L-alanyl-2-phenyl]glycine-1,1-dimethylethyl
ester (DAPT; xxx source? xxx) was used at 5 μMdissolved in 1%DMSO. Fish
were treated from the 15- to 16-somite stage to 3 dpf and themedium containing
DAPT was refreshed daily.
In situ hybridisation and immunofluorescence staining
Whole-mount in situ hybridisation in zebrafish larvae was performed as
described (Coxam et al., 2015; Duong et al., 2014). Section and whole-mount
in situ hybridisation in mouse was performed as described (Metzis et al.,
2013; Fowles et al., 2003). The Notch1 probe was generated by PCR from
mouse embryo cDNA pool at E14.5, and reverse transcribed with T7
polymerase. Whole-mount immunohistochemistry for anti-GFP was
performed as described (Koltowska et al., 2015). For details, see the
supplementary Materials and Methods.
Quantification and data analysis
To characterise the vasculature in Fig. 8E-G and Figs S6, S7, intersomitic
vessels (20-22 ISVs) expressing tg(flt1:YFP) were analysed across 10-11
somites through a z-stack using ImageJ (NIH) after image acquisition by
confocal microscopy. Intersomitic vessels connecting the dorsal
longitudinal anastomotic vessel to the dorsal aorta expressing YFP were
assigned as arterial ISVs. Vessels were also scored for ectopic sprouting.
The proportion of aISVs or hypersprouts among the total number of ISVs
was analysed by two-tailed Mann–Whitney U-test. To quantify the GFP
intensity of tg(notch1b-15:GFP) and tg(notch1b-15mutSOX-a/b:GFP)
(Fig. 7A), two to three ISVs across five to six somites in the trunk region
were analysed using ImageJ. A region of interest (ROI) covering a single
ISV was selected and mean pixel intensity for each ISV was quantified
from each individual stack across three z-sections. This value was further
corrected by subtracting the background value. Average ISV GFP
intensity (quantified from two to three ISVs) for each fish larva was
subsequently corrected for its genomic GFP copy number. A similar
method was used to quantify GFP intensity in the endothelial lining along
the dorsal aorta.
Fluorescence-activated cell sorting (FACS) and expression
analysis
Flt1:YFP-positive endothelial cells were isolated from WT and F3 notch1b-
15uq1mf/uq1 AQ27
¶
mf at 24-28 hpf. RNA was extracted, amplified and cDNA was
synthesized as previously described (Coxam et al., 2014; Picelli et al.,
2014). Primer sequences and details of the quantitative PCR analysis are
provided in the supplementary Materials and Methods.
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